UNSPSC 51314347: Chlorpheniramine/phenylephrine/phenylpropanolamine/phenyltoloxamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314347 Chlorpheniramine/phenylephrine/phenylpropanolamine/phenyltoloxamine is a Commodity code that in practice captures state and local procurement of branded and generic pharmaceuticals, over-the-counter products, and related medical supplies—though recent opportunities show significant scope divergence, with solicitations targeting naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals rather than the specific antihistamine-decongestant combination the code nominally describes. State and local issuing bodies purchasing under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The work involves establishing supply contracts for pharmaceuticals, negotiating pricing models, managing distribution through authorized wholesalers, and ensuring compliance with FDA, cGMP, and Drug Supply Chain Security Act requirements, often with fixed-price or net-price structures and administrative fees.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the most concrete opportunity a Seminole County IFB (IFB60459723LAS, response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida—a fixed-fee procurement with a two-year term and one-year renewal option, potentially FEMA-funded. The Texas HHS Commission issued a Request for Information (HHS0017013, posted April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, a market-intelligence phase preceding formal RFP issuance. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026, emphasizing price competitiveness (75 percent evaluation weight), cGMP and DSCSA compliance, and vendor participation in at least two of three authorized wholesaler networks.